{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T22:35:17Z","timestamp":1783290917796,"version":"3.54.6"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologie"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00117-023-01174-z","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T08:02:01Z","timestamp":1686902521000},"page":"549-560","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Positronenemissionstomographie in der Onkologie","Positron emission tomography in oncology"],"prefix":"10.1007","volume":"63","author":[{"given":"Christoph P.","family":"Czerner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Derlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank M.","family":"Bengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree","family":"Weiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"1174_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1148\/114.1.89","volume":"114","author":"MM Ter-Pogossian","year":"1975","unstructured":"Ter-Pogossian\u00a0MM et al (1975) A positron-emission transaxial tomograph for nuclear imaging (PETT). Radiology 114:89\u201398","journal-title":"Radiology"},{"key":"1174_CR2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.2967\/jnumed.107.047787","volume":"49","author":"JW Fletcher","year":"2008","unstructured":"Fletcher\u00a0JW et\u00a0al (2008) Recommendations on the use of 18F\u2011FDG PET in oncology. J\u00a0Nucl Med 49:480\u2013508","journal-title":"J Nucl Med"},{"key":"1174_CR3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/diagnostics12020451","volume":"12","author":"JMM Rogasch","year":"2022","unstructured":"Rogasch\u00a0JMM et\u00a0al (2022) Influences on PET quantification and interpretation. Diagnostics 12:451","journal-title":"Diagnostics"},{"key":"1174_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1055\/s-0035-1565129","volume":"38","author":"M Reifegerst","year":"2015","unstructured":"Reifegerst\u00a0M et al (2015) Physikalisch bedingte Artefakte bei \u201eneuen\u201c PET-Nukliden. Nuklearmediziner 38:234\u2013240","journal-title":"Nuklearmediziner"},{"key":"1174_CR5","volume-title":"Bekanntmachung der aktualisierten diagnostischen Referenzwerte f\u00fcr nuklearmedizinische Untersuchungen vom 15. Juni 2021. BAnz D","author":"Bundesamt f\u00fcr Strahlenschutz","year":"2021","unstructured":"Bundesamt f\u00fcr Strahlenschutz (2021) Bekanntmachung der aktualisierten diagnostischen Referenzwerte f\u00fcr nuklearmedizinische Untersuchungen vom 15. Juni 2021. BAnz D"},{"key":"1174_CR6","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1111\/febs.14577","volume":"285","author":"P Ancey","year":"2018","unstructured":"Ancey\u00a0P et\u00a0al (2018) Glucose transporters in cancer\u2014from tumor cells to the tumor microenvironment. FEBS\u00a0J 285:2926\u20132943","journal-title":"FEBS J"},{"key":"1174_CR7","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Pr\u00e4vention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms, Langversion 1.0, 2018, AWMF-Registernummer: 020\/007OL, http:\/\/leitlinienprogramm-onkologie.de\/lungenkarzinom.98.0.html. Zugegriffen: 20. Apr. 2022"},{"key":"1174_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1055\/s-2001-16201","volume":"55","author":"D Hellwig","year":"2001","unstructured":"Hellwig\u00a0D et al (2001) Metaanalyse zum Stellenwert der Positronen-Emissions-Tomographie mit F\u201118-Fluorodesoxyglukose (FDG-PET) bei Lungentumoren \u2013 Diskussionsbasis der Deutschen Konsensus-Konferenz Onko-PET 2000. Pneumologie 55:367\u2013377","journal-title":"Pneumologie"},{"key":"1174_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(20)30013-9","volume":"21","author":"U Nestle","year":"2020","unstructured":"Nestle\u00a0U et al (2020) Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-plan): A multicentre, open-label, randomised, controlled trial. Lancet Oncol 21:581\u2013592","journal-title":"Lancet Oncol"},{"key":"1174_CR10","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/S0140-6736(02)08352-6","volume":"359","author":"H van Tinteren","year":"2002","unstructured":"van Tinteren\u00a0H et al (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: The PLUS multicentre randomised trial. Lancet 359:1388\u20131392","journal-title":"Lancet"},{"key":"1174_CR11","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.2967\/jnumed.109.063040","volume":"50","author":"TJM Ruers","year":"2009","unstructured":"Ruers\u00a0TJM et\u00a0al (2009) Improved selection of patients for hepatic surgery of colorectal liver metastases with 18F\u2011FDG PET: A randomized study. J\u00a0Nucl Med 50:1036\u20131041","journal-title":"J Nucl Med"},{"key":"1174_CR12","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Diagnostik und Therapie des Mundh\u00f6hlenkarzinoms, Langversion 3.0, 2021, AWMF Registernummer: 007\/100OL https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/mundhoehlenkarzinom\/. Zugegriffen: 1. Juni 2022"},{"key":"1174_CR13","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1056\/NEJMoa1514493","volume":"374","author":"H Mehanna","year":"2016","unstructured":"Mehanna\u00a0H et al (2016) PET-CT surveillance versus neck dissection in advanced head and neck cancer. N\u00a0Engl J Med 374:1444\u20131454","journal-title":"N Engl J Med"},{"key":"1174_CR14","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Analkarzinom (Diagnostik, Therapie und Nachsorge von Analkanal- und Analrandkarzinomen), Langversion 1.2, 2020, AWMF Registernummer: 081\/004OL, https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/analkarzinom\/. Zugegriffen: 10. Juni 2022"},{"key":"1174_CR15","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie zur Diagnostik, Therapie und Nachsorge f\u00fcr Patienten mit einer Chronischen Lymphatischen Leuk\u00e4mie (CLL), Langversion 1.0, 2018, AWMF Registernummer: 018-032OL, http:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/chronische-lymphatische-leukaemie-cll\/. Zugegriffen: 6. Juni 2022"},{"key":"1174_CR16","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge f\u00fcr erwachsene Patient*innen mit einem Diffusen Gro\u00dfzelligen B\u2011Zell-Lymphom und verwandten Entit\u00e4ten, Langversion 1.01, Juni 2022, AWMF-Registernummer: 018\/038OL, https:\/\/www.leitlinienprogrammonkologie.de\/leitlinien\/dlbcl\/. Zugegriffen: 1. Juni 2022."},{"key":"1174_CR17","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Diagnostik, Therapie und Nachsorge f\u00fcr Patienten mit einem Follikul\u00e4ren Lymphom, Langversion 1.0, 2020, AWMF-Registernummer: 018\/033OL, https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/follikulaeres-lymphom\/. Zugegriffen: 10. Juni 2022"},{"key":"1174_CR18","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Diagnostik, Therapie und Nachsorge der Keimzelltumoren des Hodens, Langversion 1.1, 2020, AWMF-Registernummer: 043\/049OL, https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/hodentumoren. Zugegriffen: 20. Juni 2022"},{"key":"1174_CR19","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Hodgkin Lymphoms bei erwachsenen Patienten, Langversion 3.1, 2022; AWMF Registernummer: 018\/029 OL, https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/hodgkin-lymphom\/. Zugegriffen: 1. Juni 2022"},{"key":"1174_CR20","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Kolorektales Karzinom, Langversion 2.1, 2019, AWMF Registrierungsnummer: 021\/007OL, http:\/\/www.leitlinienprogrammonkologie.de\/leitlinien\/kolorektales-karzinom\/. Zugegriffen: 13.06.2022"},{"key":"1174_CR21","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Larynxkarzinoms, Langversion 1.1, 2019, AWMF-Registernummer: 017\/076OL, http:\/\/www.leitlinienprogrammonkologie.de\/leitlinien\/larynxkarzinom\/. Zugegriffen: 1. Mai 2022"},{"key":"1174_CR22","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.4, 2021, AWMF Registernummer: 032-045OL, http:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/mammakarzinom\/. Zugegriffen: 20. Juni 2022"},{"key":"1174_CR23","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Melanoms, Langversion 3.3, 2020, AWMF Registernummer: 032\/024OL, http:\/\/www.leitlinienprogrammonkologie.de\/leitlinien\/melanom\/. Zugegriffen: 22. Juni 2022"},{"key":"1174_CR24","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge f\u00fcr Patienten mit Monoklonaler Gammopathie Unklarer Signifikanz (MGUS) oder Multiplen Myelom, Langversion 1.0, 2022, AWMF-Registernummer: 018\/035OL, https:\/\/www.leitlinienprogrammonkologie.de\/leitlinien\/multiples-myelom\/. Zugegriffen: 25. Juni 2022"},{"key":"1174_CR25","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Langversion 5.1, 2022, AWMF-Registernummer: 032\/035OL, https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/ovarialkarzinom\/. Zugegriffen: 01.06.2022"},{"key":"1174_CR26","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des \u00d6sophagus; Langversion 3.1, 2022, AWMF-Registernummer: 021\/023OL, https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/oesophaguskarzinom\/. Zugegriffen: 2. Juli 2022."},{"key":"1174_CR27","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie exokrines Pankreaskarzinom, Langversion 2.0, 2021, AWMF Registernummer: 032-010OL, https:\/\/www.leitlinienprogrammonkologie.de\/leitlinien\/pankreaskarzinom\/. Zugegriffen: 1. Juni 2022"},{"key":"1174_CR28","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prostatakarzinom, Langversion 6.0, 2021, AWMF Registernummer: 043\/022OL, http:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/prostatakarzinom\/. Zugegriffen: 5. Juni 2022"},{"key":"1174_CR29","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom, Langversion, 2.2, 2022, AWMF-Registernummer: 032\/033OL, https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/zervixkarzinom\/, [Stand: 01.05.2022]."},{"key":"1174_CR30","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","volume":"390","author":"P Borchmann","year":"2017","unstructured":"Borchmann\u00a0P et al (2017) PET-guided treatment in patients with advanced-stage hodgkin\u2019s lymphoma (HD18): Final results of an open-label, international, randomised phase 3 trial by the german hodgkin study group. Lancet 390:2790\u20132802","journal-title":"Lancet"},{"key":"1174_CR31","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","volume":"379","author":"A Engert","year":"2012","unstructured":"Engert\u00a0A et al (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage hodgkin\u2019s lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. Lancet 379:1791\u20131799","journal-title":"Lancet"},{"key":"1174_CR32","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","volume":"37","author":"SF Barrington","year":"2010","unstructured":"Barrington\u00a0SF et\u00a0al (2010) Concordance between four european centres of PET reporting criteria designed for use in multicentre trials in hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37:1824\u20131833","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1174_CR33","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.2967\/jnumed.109.074294","volume":"51","author":"Z Rabkin","year":"2010","unstructured":"Rabkin\u00a0Z, Israel\u00a0O, Keidar\u00a0Z (2010) Do hyperglycemia and diabetes affect the incidence of false-negative 18F\u2011FDG PET\/CT studies in patients evaluated for infection or inflammation and cancer? A comparative analysis. J\u00a0Nucl Med 51:1015\u20131020","journal-title":"J Nucl Med"},{"key":"1174_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","volume":"37","author":"R Boellaard","year":"2010","unstructured":"Boellaard\u00a0R et\u00a0al (2010) FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0. Eur J Nucl Med Mol Imaging 37:181\u2013200","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1174_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.prnil.2017.02.003","volume":"5","author":"C Udovicich","year":"2017","unstructured":"Udovicich\u00a0C et\u00a0al (2017) 68Ga-prostate-specific membrane antigen-positron emission tomography\/computed tomography in advanced prostate cancer: Current state and future trends. Prostate Int 5:125\u2013129","journal-title":"Prostate Int"},{"key":"1174_CR36","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","volume":"82","author":"DG Bostwick","year":"1998","unstructured":"Bostwick\u00a0DG et\u00a0al (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma. Cancer 82:2256\u20132261","journal-title":"Cancer"},{"key":"1174_CR37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.eururo.2015.06.010","volume":"69","author":"L Bud\u00e4us","year":"2016","unstructured":"Bud\u00e4us\u00a0L et\u00a0al (2016) Initial experience of 68Ga-PSMA PET\/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 69:393\u2013396","journal-title":"Eur Urol"},{"key":"1174_CR38","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler\u00a0WP et\u00a0al (2019) Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer. JAMA Oncol 5:856","journal-title":"JAMA Oncol"},{"key":"1174_CR39","first-page":"e5","volume":"482","author":"HA Vargas","year":"2016","unstructured":"Vargas\u00a0HA et al (2016) Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1 ng\/ml following prostatectomy: How much information can conventional imaging provide? Urol Oncol Seminars Orig Investig 482:e5\u2013e10","journal-title":"Urol Oncol Seminars Orig Investig"},{"key":"1174_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00259-007-0581-4","volume":"35","author":"BJ Krause","year":"2008","unstructured":"Krause\u00a0BJ et\u00a0al (2008) The detection rate of 11C\u2011choline-PET\/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35:18\u201323","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1174_CR41","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2967\/jnumed.117.197160","volume":"59","author":"PJ Roach","year":"2018","unstructured":"Roach\u00a0PJ et\u00a0al (2018) The impact of 68ga-PSMA PET\/CT on management intent in prostate cancer: results of an australian prospective multicenter study. J\u00a0Nucl Med 59:82\u201388","journal-title":"J Nucl Med"},{"key":"1174_CR42","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips\u00a0R et\u00a0al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer. JAMA Oncol 6:650","journal-title":"JAMA Oncol"},{"key":"1174_CR43","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman\u00a0MS et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208\u20131216","journal-title":"Lancet"},{"key":"1174_CR44","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman\u00a0MS et\u00a0al (2021) 177Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397:797\u2013804","journal-title":"Lancet"},{"key":"1174_CR45","unstructured":"Wick W et al (2021) Gliome, S2k-Leitlinie, in: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. www.dgn.org\/leitlinien. Zugegriffen: 1. Juli 2022"},{"key":"1174_CR46","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1007\/s00259-019-04656-2","volume":"47","author":"S Song","year":"2020","unstructured":"Song\u00a0S et al (2020) Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET\/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study. Eur J Nucl Med Mol Imaging 47:1458\u20131467","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1174_CR47","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/neuonc\/now058","volume":"18","author":"NL Albert","year":"2016","unstructured":"Albert\u00a0NL et al (2016) Response assessment in neuro-oncology working group and european association for neuro-oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 18:1199\u20131208","journal-title":"Neuro Oncol"},{"key":"1174_CR48","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/neuonc\/noab013","volume":"23","author":"N Galldiks","year":"2021","unstructured":"Galldiks\u00a0N et\u00a0al (2021) Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients\u2014a report of the PET\/RANO group. Neuro Oncol 23:881\u2013893","journal-title":"Neuro Oncol"},{"key":"1174_CR49","unstructured":"S2k-Leitlinie Neuroendokrine Tumore, AWMF-Reg. 021-27. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/021-026l_S2k_neuroendokrine_tumore_2018-07.pdf. Zugegriffen: 1. Juli 2022"},{"key":"1174_CR50","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/JCO.2015.64.0987","volume":"34","author":"SM Sadowski","year":"2016","unstructured":"Sadowski\u00a0SM et\u00a0al (2016) Prospective study of 68Ga-DOTATATE positron emission tomography\/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J\u00a0Clin Oncol 34:588\u2013596","journal-title":"J Clin Oncol"},{"key":"1174_CR51","doi-asserted-by":"publisher","first-page":"756","DOI":"10.2967\/jnumed.116.185587","volume":"58","author":"M Barrio","year":"2017","unstructured":"Barrio\u00a0M et al (2017) The impact of somatostatin receptor\u2013directed PET\/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis. J\u00a0Nucl Med 58:756\u2013761","journal-title":"J Nucl Med"},{"key":"1174_CR52","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil\u00a0C et\u00a0al (2019) 68Ga-FAPI PET\/CT: Tracer uptake in 28 different kinds of cancer. J\u00a0Nucl Med 60:801\u2013805","journal-title":"J Nucl Med"}],"container-title":["Die Radiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-023-01174-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00117-023-01174-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-023-01174-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T13:03:30Z","timestamp":1687871010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00117-023-01174-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1174"],"URL":"https:\/\/doi.org\/10.1007\/s00117-023-01174-z","relation":{},"ISSN":["2731-7048","2731-7056"],"issn-type":[{"value":"2731-7048","type":"print"},{"value":"2731-7056","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"assertion":[{"value":"16 June 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>C.P.\u00a0Czerner<\/b>: A.\u00a0Finanzielle Interessen: C.P.\u00a0Czerner gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Aktuell Assistenzarzt in der Klinik f\u00fcr Nuklearmedizin der Medizinischen Hochschule Hannover, Hannover; Facharzt f\u00fcr Radiologie, European Diploma in Radiology (EDiR) | Mitgliedschaften: Deutsche R\u00f6ntgengesellschaft, European Society of Radiology, Deutsche Gesellschaft f\u00fcr Ultraschall in der Medizin. <b>T.\u00a0Derlin<\/b>: A.\u00a0Finanzielle Interessen: T.\u00a0Derlin gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Nuklearmediziner, Klinik f\u00fcr Nuklearmedizin, Medizinische Hochschule Hannover, Hannover | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Nuklearmedizin e.\u202fV. (DGN), Berufsverband Deutscher Nuklearmediziner e.\u202fV. (BDN), Society of Nuclear Medicine and Molecular Imaging (SNMMI). <b>F.M.\u00a0Bengel<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Siemens Healthineers, Forschungsvereinbarung zum Thema \u201eParametric PET\u201c. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Direktor der Klinik f\u00fcr Nuklearmedizin der Medizinischen Hochschule Hannover; Forschungsdekan der Medizinischen Hochschule Hannover; Vorstandsmitglied der DGN. <b>D.\u00a0Weiberg<\/b>: A.\u00a0Finanzielle Interessen: Fortbildungsgutschein i.\u202fH.\u202fv. 250\u202f\u20ac vom Verein zur F\u00f6rderung der Fort- und Weiterbildung i.\u202fd. Gastroenterologie, Hepatologie und Endokrinologie (GHE) e.\u202fV. (MHH) f\u00fcr eine Referentent\u00e4tigkeit anl\u00e4sslich der Fortbildungsveranstaltung: \u201eNeuroendokrine Neoplasien\u201c am 06.10.2021.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Ober\u00e4rztin in der Klinik f\u00fcr Nuklearmedizin, Medizinische Hochschule Hannover, Hannover | Mitgliedschaft: DGN.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}